牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$Can-fite Biopharma(CANF)$ F-3/A [Amend] Registration statement by foreign private issuers Accession Number: 0001213900-23-099250 Act: 33 Size: 382 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-097112 Act: 34 Size: 22 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-096289 Act: 34 Size: 22 KB 网页链接
$Can-fite Biopharma(CANF)$ F-3 Registration statement by foreign private issuers Accession Number: 0001213900-23-095107 Act: 33 Size: 439 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-092327 Act: 34 Size: 25 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-091211 Act: 34 Size: 74 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-089590 Act: 34 Size: 317 KB 网页链接
$Can-fite Biopharma(CANF)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001213900-23-089597 Act: 33 Size: 25 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-089270 Act: 34 Size: 24 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-088936 Act: 34 Size: 24 KB 网页链接